Pharmaceutical Supplemental Rebate

NMSA 1978 ch. 27, art. 2C

in effect

NMSA 1978, § 27-2C-1 Short title

27-2C-1. Short title Chapter 27, Article 2C NMSA 1978 may be cited as the "Pharmaceutical Supplemental Rebate Act". Laws 2002, ch. 105, § 1; 2024, ch. 39, § 89.

NMSA 1978, § 27-2C-2 Definitions

27-2C-2. Definitions As used in the Pharmaceutical Supplemental Rebate Act: A. "authority" or "department" means the health care authority; B. "labeler" means a person that receives prescription drugs from a manufacturer or wholesaler and repackages those drugs for later retail sale and that has a labeler code from the federal food and drug administration; C. "manufacturer" means a manufacturer of prescription drugs as defined in 42 U.S.C. 1396r-8(k)(5), including a subsidiary or affiliate of a manufacturer; D. "medicaid" means the joint federal-state health coverage program pursuant to Title 19 or Title 21 of the federal Social Security Act; E. "participating retail pharmacy" means a retail pharmacy or other business licensed to dispense prescription drugs that participates in the state medicaid program; F. "secretary" means the secretary of health care authority; and G. "wholesaler" means a business licensed to distribute prescription drugs in the state. Laws 2002, ch. 105, § 2; 2024, ch. 39, § 90.

NMSA 1978, § 27-2C-3 Medicaid formulary for prescription drugs

27-2C-3. Medicaid formulary for prescription drugs A. The department shall develop or implement a formulary or preferred drug list, taking into consideration the clinical efficacy, safety and cost effectiveness of a product. B. The department shall ensure that the administration or delivery of health care services and products under the medicaid program includes a formulary that will provide medically appropriate drug therapies for patients. C. The department shall require a prior authorization before a drug not listed on the medicaid program formulary may be dispensed unless otherwise provided pursuant to Subsection C of Section 27-2C-4 NMSA 1978. D. The department shall ensure that atypical antipsychotic medications are available in the same manner as conventional antipsychotic medications for medicaid patients for the treatment of severe mental illnesses that are listed in a current national diagnostic and statistical manual of mental disorders published by a national psychiatric association, including schizophrenia, clinical depression, bipolar disorder, anxiety-panic attack disorder and obsessive compulsive disorder. Laws 2002, ch. 105, § 3; 2003, ch. 344, § 1.

NMSA 1978, § 27-2C-4 Negotiated drug discounts and rebates

27-2C-4. Negotiated drug discounts and rebates A. The secretary shall negotiate discount prices or rebates for prescription drugs from drug manufacturers and labelers that include supplemental rebates for the medicaid program over and above those required under 42 U.S.C. 1396r-8. B. In negotiating rebate terms, the secretary shall consider the rebate calculated under the medicaid rebate program pursuant to 42 U.S.C. 1396r-8, the price provided to eligible entities under 42 U.S.C. 256b and other available information on prescription drug prices, discounts and rebates. C. The secretary shall prompt a review of whether to place a manufacturer's or labeler's products on the prior authorization list for the medicaid program if: (1) the secretary and a drug manufacturer or labeler fail to reach agreement on the terms of a supplemental medicaid rebate or discount; and (2) the discounts or rebates offered by the manufacturer or labeler are not as favorable to the state as the prices provided to eligible entities under 42 U.S.C. 256b. D. Any prior authorization shall meet the requirements of 42 U.S.C. 1396r-8(d)(5) and be done in accordance with the Public Assistance Act [27-2-1 NMSA 1978] or department rules. E. The names of manufacturers and labelers that do not enter into rebate agreements are public information, and the department shall release this information to the public and actively distribute it to physicians, pharmacists and other health care professionals. Laws 2002, ch. 105, § 4.

NMSA 1978, § 27-2C-5 Reporting

27-2C-5. Reporting The department shall report the savings from the pharmaceutical supplemental rebates for the preceding fiscal year to the legislative health and human services committee by November 1 of each year. Laws 2002, ch. 105, § 5.

NMSA 1978, § 27-2C-6 Coordination with other programs

27-2C-6. Coordination with other programs When the secretary finds that it is beneficial to the medicaid program and another state program to combine drug pricing negotiations to maximize drug rebates, the secretary may do so. Laws 2002, ch. 105, § 6.

NMSA 1978, § 27-2C-7 Rulemaking

27-2C-7. Rulemaking The department shall adopt rules to implement the provisions of the Pharmaceutical Supplemental Rebate Act [27-2C-1 NMSA 1978]. Laws 2002, ch. 105, § 7.

NMSA 1978, § 27-2C-8 Waivers

27-2C-8. Waivers The department shall seek any waivers of federal law or rule necessary to implement the provisions of the Pharmaceutical Supplemental Rebate Act [27-2C-1 NMSA 1978]. Laws 2002, ch. 105, § 8.

Source: New Mexico Compilation Commission (nmonesource.com)URL: https://nmonesource.com/nmos/nmsa-unanno/en/item/18527/index.doFetched: 10/20/2026